YY1 is a novel potential therapeutic target for the treatment of HPV infection YInduced cervical cancer by arsenic trioxide

International Journal of Gynecological Cancer

Volumn 21, Issue 6, 2011, Pages 1097-1104

  He, Guifen ^a   Wang, Qian ^a   Zhou, Yuqi ^b   Wu, Xiaohua ^b   Wang, Lan ^a   Duru, Nadire ^c   Kong, Xiangtao ^a   Zhang, Pingzhao ^a   Wan, Bo ^a   Sui, Long ^a   Guo, Qisang ^a   Li, Jian Jian ^c   Yu, Long ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arsenic trioxide; Cervical cancer; Therapeutic target; YY1

Indexed keywords

ARSENIC TRIOXIDE; MESSENGER RNA; PROTEIN P53; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR YY1;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER TISSUE; CELL CYCLE PARAMETERS; COLONY FORMATION; CONTROLLED STUDY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; DNA PRIMERS; FEMALE; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; OXIDES; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; UTERINE CERVICAL NEOPLASMS; YY1 TRANSCRIPTION FACTOR;

EID: 83055165661     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821d2525     Document Type: Article

References (39)

1. Fanta BE. The distribution of human papilloma virus infection in women with cervical histological abnormalities from an area with high incidence of cervical cancer. Ethiop Med J. 2005;43:151Y158. (Pubitemid 44767440)
2. Scheffner M, Huibregtse JM, Vierstra RD, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75:495Y505. (Pubitemid 23335075)
3. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129Y1136. (Pubitemid 120035062)
4. Hengstermann A, Linares LK, Ciechanover A, et al. Complete switch from Mdm2 to human papillomavirus E6Ymediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci U S A. 2001;98:1218Y1223. (Pubitemid 32121213)
5. Chen X, Shen B, Xia L, et al. Activation of nuclear factor JB in radioresistance of TP53-inactive human keratinocytes. Cancer Res. 2002;62:1213Y1221. (Pubitemid 34160311)
6. Hawley-Nelson P, Vousden KH, Hubbert NL, et al. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989;8:3905Y3910. (Pubitemid 20016074)
7. Li JJ, Cao Y, Young MR, et al. Induced expression of dominant-negative c-jun downregulates NFJB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes. Mol Carcinog. 2000;29:159Y169.
8. Li JJ, Rhim JS, Schlegel R, et al. Expression of dominant negative Jun inhibits elevated AP-1 and NF-JB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene. 1998;16:2711Y2721. (Pubitemid 28279336)
9. Pei XF, Meck JM, Greenhalgh D, et al. Cotransfection of HPV-18 and v-fos DNA induces tumorigenicity of primary human keratinocytes. Virology. 1993;196:855Y860.
10. Butz K, Ristriani T, Hengstermann A, et al. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirusYpositive cancer cells. Oncogene. 2003;22:5938Y5945. (Pubitemid 37175872)
11. Bauknecht T, Jundt F, Herr I, et al. A switch region determines the cell typeYspecific positive or negative action of YY1 on the activity of the human papillomavirus type 18 promoter. J Virol. 1995;69:1Y12. (Pubitemid 24378772)
12. Bauknecht T, See RH, Shi Y. A novel C/EBP A-YY1 complex controls the cell-typeYspecific activity of the human papillomavirus type 18 upstream regulatory region. J Virol. 1996;70:7695Y7705. (Pubitemid 26339075)
13. Bauknecht T, Shi Y. Overexpression of C/EBPA represses human papillomavirus type 18 upstream regulatory region activity in HeLa cells by interfering with the binding of TATA-binding protein. J Virol. 1998;72:2113Y2124. (Pubitemid 28100767)
14. Dong XP, Pfister H. Overlapping YY1Y and aberrant SP1Ybinding sites proximal to the early promoter of human papillomavirus type 16. J Gen Virol. 1999;80(Pt 8):2097Y2101. (Pubitemid 29389147)
15. Flanagan JR, Becker KG, Ennist DL, et al. Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus. Mol Cell Biol. 1992;12:38Y44.
16. Hariharan N, Kelley DE, Perry RP. Delta, a transcription factor that binds to downstream elements in several polymerase II promoters, is a functionally versatile zinc finger protein. Proc Natl Acad Sci U S A. 1991;88:9799Y9803. (Pubitemid 21915721)
17. Shi Y, Lee JS, Galvin KM. Everything you have ever wanted to know about Yin Yang 1. Biochim Biophys Acta. 1997;1332:F49YF66. (Pubitemid 27211616)
18. Begon DY, Delacroix L, Vernimmen D, et al. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem. 2005;280:24428Y24434. (Pubitemid 40934527)
19. Park K, Atchison ML. Isolation of a candidate repressor/activator, NF-E1 (YY-1, delta), that binds to the immunoglobulin J 3¶ enhancer and the immunoglobulin heavy-chain mu E1 site. Proc Natl Acad Sci U S A. 1991;88:9804Y9808. (Pubitemid 21915722)
20. Shi Y, Seto E, Chang LS, Shenk T. Transcriptional repression by YY1, a human GLI-KruppelYrelated protein, and relief of repression by adenovirus E1A protein. Cell. 1991;67:377Y388. (Pubitemid 121001453)
21. Erkeland SJ, Valkhof M, Heijmans-Antonissen C, et al. The gene encoding the transcriptional regulator Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neutrophilic differentiation. Blood. 2003;101:1111Y1117. (Pubitemid 36139386)
22. de Nigris F, Botti C, de Chiara A, et al. Expression of transcription factor Yin Yang 1 in human osteosarcomas. Eur J Cancer. 2006;42:2420Y2424. (Pubitemid 44442948)
23. Seligson D, Horvath S, Huerta-Yepez S, et al. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol. 2005;27:131Y141.
24. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354Y3360.
25. Shen Y, Shen ZX, Yan H, et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia. 2001;15:735Y741. (Pubitemid 32492696)
26. Soignet SL. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist. 2001;6(suppl 2):11Y16. (Pubitemid 32405844)
27. Um SJ, Lee SY, Kim EJ, et al. Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells. Cancer Lett. 2002;181:11Y22.
28. Kerfoot C, Huang W, Rotenberg SA. Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C>. J Histochem Cytochem. 2004;52:419Y422. (Pubitemid 38229108)
29. Crinelli R, Bianchi M, Menotta M, et al. Ubiquitin over-expression promotes E6AP autodegradation and reactivation of the p53/MDM2 pathway in HeLa cells. Mol Cell Biochem. 2008;318:129Y145.
30. Ito A, Kawaguchi Y, Lai CH, et al. MDM2-HDAC1Ymediated deacetylation of p53 is required for its degradation. EMBO J. 2002;21:6236Y6245. (Pubitemid 35415340)
31. Kobet E, Zeng X, Zhu Y, et al. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci U S A. 2000;97: 12547Y12552.
32. Koivusalo R, Mialon A, Pitkanen H, et al. Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient, but can be sustained by inhibiting endogenous nuclear exportYdependent p53 antagonists. Cancer Res. 2006;66:11817Y11824. (Pubitemid 46094193)
33. Li M, Luo J, Brooks CL, et al. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem. 2002;277:50607Y50611. (Pubitemid 36042220)
34. Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med. 2007;85:1175Y1186. (Pubitemid 47622219)
35. Wynford-Thomas D. p53: guardian of cellular senescence. J Pathol. 1996;180:118Y121. (Pubitemid 26370174)
36. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420:25Y27. (Pubitemid 28037193)
37. Gronroos E, Terentiev AA, Punga T, et al. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc Natl Acad Sci U S A. 2004;101: 12165Y12170. (Pubitemid 39145414)
38. Sui G, Affar el B, Shi Y, et al. Yin Yang 1 is a negative regulator of p53. Cell. 2004;117:859Y872. (Pubitemid 38798853)
39. Baritaki S, Sifakis S, Huerta-Yepez S, et al. Overexpression of VEGF and TGF-A1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. Int J Oncol. 2007;31:69Y79.